RESUMO
The Italian Society of Colorectal Surgery (SICCR) promoted the project reported here, which consists of a Position Statement of Italian colorectal surgeons to address the surgical aspects of ulcerative colitis management. Members of the society were invited to express their opinions on several items proposed by the writing committee, based on evidence available in the literature. The results are presented, focusing on relevant points. The present paper is not an alternative to available guidelines; rather, it offers a snapshot of the attitudes of SICCR surgeons about the surgical treatment of ulcerative colitis. The committee was able to identify some points of major disagreement and suggested strategies to improve the quality of available data and acceptance of guidelines.
Assuntos
Colite Ulcerativa , Colite , Cirurgia Colorretal , Doenças Inflamatórias Intestinais , Proctocolectomia Restauradora , Colite/cirurgia , Colite Ulcerativa/cirurgia , Humanos , Doenças Inflamatórias Intestinais/cirurgia , ItáliaRESUMO
The affiliation of the author Silvio Danese has been incorrectly published in the original publication.
Assuntos
Procedimentos Cirúrgicos do Sistema Digestório/métodos , Pomadas/administração & dosagem , Seio Pilonidal/cirurgia , Cicatrização/efeitos dos fármacos , Administração Tópica , Adolescente , Adulto , Alginatos/administração & dosagem , Aloe , Colostro , Feminino , Glicerol/administração & dosagem , Humanos , Ácido Hialurônico/administração & dosagem , Itália , Masculino , Pessoa de Meia-Idade , Pomadas/química , Período Pós-Operatório , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: In recent years, improvement of Health-Related Quality of Life (HRQoL) in Ulcerative colitis (UC) has become a relevant measure for treatment efficacy. METHODS: We report results from a multicenter prospective study in Italy investigating HRQoL in adult patients with UC treated with golimumab (GLM). Patients who had shown clinical response after a 6-week induction phase (w0), were followed for an additional 48 weeks (w48) (total 54-week treatment). RESULTS: Of the 159 patients enrolled 90 completed the study. Compared to values at the beginning of treatment (n = 137), significant improvements were observed for mean total Inflammatory Bowel Disease Questionnaire (IBDQ) scores at w0 (168.5) and w48 (181.7). Patients with baseline PMS above the median tended to have greater improvements in IBDQ at w0 (OR 2.037, p = 0.033) and w48 (OR 3.292, p = 0.027). Compared to beginning of GLM treatment, the mean Full Mayo Score (FMS) decreased by 5.9 points at w48, while mean Partial Mayo Score (PMS) decreased by 3.9 points at w0 and by 4.9 points at w48. CONCLUSIONS: GLM improved HRQoL, disease activity and inflammatory biomarkers in UC patients with moderate-to-severely active disease. The greater the burden of disease activity at baseline, the greater the improvement of HRQoL after 24 and 48 weeks of treatment.